240 related articles for article (PubMed ID: 37326271)
1. PPIs and gastric cancer: any causal relationship?
Crafa P; Franceschi M; Rodriguez-Castro KI; Franzoni L; Russo M; Brandimarte G; Tursi A; Rugge M; Di Mario F
Acta Biomed; 2023 Jun; 94(3):e2023096. PubMed ID: 37326271
[TBL] [Abstract][Full Text] [Related]
2. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions.
Song H; Zhu J; Lu D
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010623. PubMed ID: 25464111
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors and H. pylori infection: why the concern?
Weinstein WM
Curr Gastroenterol Rep; 1999 Dec; 1(6):507-10. PubMed ID: 10980994
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Proton Pump Inhibitors on the Development of Gastric Neoplastic Lesions in Patients With Autoimmune Atrophic Gastritis.
Dilaghi E; Bellisario M; Esposito G; Carabotti M; Annibale B; Lahner E
Front Immunol; 2022; 13():910077. PubMed ID: 35935934
[TBL] [Abstract][Full Text] [Related]
5. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.
Trinh VQ; Shi C; Ma C
Histopathology; 2020 Dec; 77(6):865-876. PubMed ID: 32702178
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use.
Parsons BN; Ijaz UZ; D'Amore R; Burkitt MD; Eccles R; Lenzi L; Duckworth CA; Moore AR; Tiszlavicz L; Varro A; Hall N; Pritchard DM
PLoS Pathog; 2017 Nov; 13(11):e1006653. PubMed ID: 29095917
[TBL] [Abstract][Full Text] [Related]
7. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions?
Eslami L; Nasseri-Moghaddam S
Arch Iran Med; 2013 Aug; 16(8):449-58. PubMed ID: 23906249
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
9. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis.
Sanduleanu S; Jonkers D; De Bruïne A; Hameeteman W; Stockbrügger RW
Aliment Pharmacol Ther; 2001 Aug; 15(8):1163-75. PubMed ID: 11472319
[TBL] [Abstract][Full Text] [Related]
10. Proton Pump Inhibitor Induction of Gastric Cobblestone-like Lesions in the Stomach.
Takahari K; Haruma K; Ohtani H; Kiyoto S; Watanabe A; Kamada T; Manabe N; Hatano Y
Intern Med; 2017 Oct; 56(20):2699-2703. PubMed ID: 28924108
[TBL] [Abstract][Full Text] [Related]
11. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis.
Li Z; Wu C; Li L; Wang Z; Xie H; He X; Feng J
Saudi J Gastroenterol; 2017; 23(4):222-228. PubMed ID: 28721975
[TBL] [Abstract][Full Text] [Related]
12. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.
Ko Y; Tang J; Sanagapalli S; Kim BS; Leong RW
Expert Opin Drug Saf; 2016 Jan; 15(1):53-63. PubMed ID: 26560097
[TBL] [Abstract][Full Text] [Related]
13. Associated factors of atrophic gastritis diagnosed by double-contrast upper gastrointestinal barium X-ray radiography: a cross-sectional study analyzing 6,901 healthy subjects in Japan.
Yamamichi N; Hirano C; Shimamoto T; Minatsuki C; Takahashi Y; Nakayama C; Matsuda R; Fujishiro M; Konno-Shimizu M; Kato J; Kodashima S; Ono S; Niimi K; Mochizuki S; Tsuji Y; Sakaguchi Y; Asada-Hirayama I; Takeuchi C; Yakabi S; Kakimoto H; Wada R; Mitsushima T; Ichinose M; Koike K
PLoS One; 2014; 9(10):e111359. PubMed ID: 25343257
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of the proton-pump inhibitors.
Reilly JP
Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S11-7. PubMed ID: 10597119
[TBL] [Abstract][Full Text] [Related]
15. Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers.
Russo M; Rodriguez-Castro KI; Franceschi M; Ferronato A; Panozzo MP; Brozzi L; Di Mario F; Crafa P; Brandimarte G; Tursi A
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768710
[TBL] [Abstract][Full Text] [Related]
16. Role of chronic atrophic gastritis of the body-fundus and achlorhydria in the development of epithelial dysplasia and gastric carcinoma.
Testino G; De Iaco F; Cornaggia M
Acta Gastroenterol Belg; 2004; 67(4):327-30. PubMed ID: 15727076
[TBL] [Abstract][Full Text] [Related]
17. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
McCarthy DM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
[TBL] [Abstract][Full Text] [Related]
18. Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes.
Nasser SC; Slim M; Nassif JG; Nasser SM
World J Gastroenterol; 2015 Apr; 21(15):4599-606. PubMed ID: 25914469
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.
Waldum HL; Sørdal Ø; Fossmark R
Scand J Gastroenterol; 2018 Jun; 53(6):639-642. PubMed ID: 29852782
[TBL] [Abstract][Full Text] [Related]
20. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors.
Minalyan A; Gabrielyan L; Scott D; Jacobs J; Pisegna JR
Curr Gastroenterol Rep; 2017 Aug; 19(8):42. PubMed ID: 28733944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
